File(s) not publicly available
ParkinSong: outcomes of a 12-month controlled trial of Therapeutic Singing Groups in Parkinson’s disease
journal contributionposted on 2021-02-02, 04:15 authored by Jeanette Tamplin, Meg MorrisMeg Morris, Caterina Marigliani, Felicity A Baker, Gustavo Noffs, Adam P Vogel
© 2020 - IOS Press and the authors. All rights reserved. Background: Parkinson's disease (PD) frequently causes progressive deterioration in speech, voice and cognitive aspects of communication. These affect wellbeing and quality of life and are associated with caregiver strain and burden. Therapeutic singing groups can ameliorate PD-related communication disorders and increase social interaction and wellbeing for caregivers and care recipients. Objective: To analyse the effects of ParkinSong group singing sessions on Parkinson's communication and wellbeing outcomes for people with PD and caregivers over 12 months. Methods: A 4-armed controlled clinical trial compared ParkinSong with active non-singing control conditions over 12 months. Two dosage levels (weekly versus monthly) were available for each condition. ParkinSong comprised high-effort vocal, respiratory and speech exercises, group singing, and social interaction. PD-specific outcomes included vocal loudness, speech intelligibility, maximum phonation time, respiratory muscle strength, and voice related quality of life (QoL). Wellbeing outcomes were also measured for caregivers and care recipients. Results: We recruited 75 people with PD and 44 caregivers who attended weekly ParkinSong, monthly ParkinSong, weekly control or monthly control groups. We found significant improvements in the primary outcome of vocal loudness (p=0.032), with weekly singers 5.13 dB louder (p=0.044) and monthly singers 5.69 dB louder (p=0.015) than monthly controls at 12 months. ParkinSong participants also showed greater improvements in voice-related QoL and anxiety. Caregivers who attended ParkinSong showed greater reductions in depression and stress scores. Conclusions: This 12-month controlled clinical trial of ParkinSong demonstrated improvements in speech loudness and voice-related QoL for participants with PD, and enhanced wellbeing for both caregivers and care recipients. No adverse effects were reported over 12 months and improvements were sustained.
This research was funded by The University of Melbourne, La Trobe University, and Parkinson's Victoria (Australia). J Tamplin and A Vogel were supported by National Health and Medical Research Council Fellowships (#1106603 and #1135683 respectively). We would like to acknowledge and thank Monash Health and the Hugh Williamson Foundation for their support of this research. Special thanks also to the people living with Parkinson's who gave so generously of their time to participate in this research.
JournalJournal of Parkinson's Disease
Pagination14p. (p. 1217-1230)
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineNeurosciencesNeurosciences & NeurologyParkinson's diseasemovement disordersrehabilitationcommunicationspeechloudnesssingingmusic therapyvoice-related quality of lifenon-motor symptomsGROUP MUSIC-THERAPYQUALITY-OF-LIFEIMMUNOGLOBULIN-AVOICE DISORDERSSPEECHPEOPLEINDIVIDUALSDEMENTIAMOTORGAITClinical Trial Registry number: ACTRN12617000528358